依达拉奉对急性脑出血并发SIRS致MODS的干预影响

摘要

. DepartmentofNeurology,MianyangCentralHospital,SichuanProvince,Mianyang621000,China;2. Department of Laboratory, Mianyang Central Hospital,Sichuan Province,Mi-anyang 621000,China;Objective:To observe the ef ects of Edaravone on the serum level of TNF-α、NOin patients of AICH with SIRS、with MODS. Method:59 ACH with SIRS、MODS was randomly devided into two groups:routine treatment group and Edaravone group(treated with edaravone in addition to the routin treatment), Edaravone was injected at a dose of 30mg, twice a day,for 14 days. ) . The serum level of TNF-α、NO and NIHSS scores in two groups were assessed at dif erent point before treatment andtwoweeksafter treatment. Results:The incident rate of AICH with SIRS was 45. 76%. MODS was 32. 2%. TNF-α、NO in serum of patients of Edaravone group decreased significantly(P<0. 05). Conclusion:Edaravone could reduce the serum level of TNF-α、NOand accelerate the recovery of neurological function deficit.%目的：观察依达拉奉用于治疗急性脑出血(ACH)并发全身炎症反应综合征(SIRS)致多脏器功能障碍综合症(MODS)时肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)的变化。方法：统计59例ACH诱发SIRS、MODS发生率,ACH合并SIRS患者随机分为常规组和依达拉奉组,常规组给予减轻脑水肿、控制血压、血糖等治疗。依达拉奉组加用依达拉奉(商品名为必存,南京先声药业有限公司生产)30mg加入0.9%NS250ml静滴,2次/d共2周。治疗前后比较血清TNF-α、NO水平以及美国国立卫生院卒中患者神经机能缺损评分量表(NIHSS)的比较。结果：1、59例ACH患者诱发SIRS27例、MODS19例,发生率分别为45.76%、32.20%；2、依达拉奉组血清TNF-α、NO水平较常规组下降明显, NIHSS评分减少(P<0.05)。结论：依达拉奉治疗可降低ACH并SIRS、MODS时血清TNF-α、NO水平,其对脑出血时神经元的保护作用与抗炎作用有关。